{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:23:34Z","timestamp":1773109414622,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-147073NB-I00"],"award-info":[{"award-number":["PID2023-147073NB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007319","name":"Centro de Matem\u00e1tica, Universidade do Minho","doi-asserted-by":"publisher","award":["UID\/00013"],"award-info":[{"award-number":["UID\/00013"]}],"id":[{"id":"10.13039\/501100007319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FCT\/MCTES","award":["CoSysM32022.03091.PTDC"],"award-info":[{"award-number":["CoSysM32022.03091.PTDC"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Math Biol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inflammatory bowel disease (IBD), including Crohn s disease (CD) and ulcerative colitis (UC), is characterized by chronic intestinal inflammation driven by elevated tumor necrosis factor-alpha (TNF-\n                    <jats:inline-formula>\n                      <jats:alternatives>\n                        <jats:tex-math>$$\\alpha $$<\/jats:tex-math>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                          <mml:mi>\u03b1<\/mml:mi>\n                        <\/mml:math>\n                      <\/jats:alternatives>\n                    <\/jats:inline-formula>\n                    ). Infliximab, an anti-TNF-\n                    <jats:inline-formula>\n                      <jats:alternatives>\n                        <jats:tex-math>$$\\alpha $$<\/jats:tex-math>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                          <mml:mi>\u03b1<\/mml:mi>\n                        <\/mml:math>\n                      <\/jats:alternatives>\n                    <\/jats:inline-formula>\n                    monoclonal antibody, is widely used in the treatment of inflammatory bowel disease but shows variable effectiveness due to interindividual pharmacokinetic diversity. We develop a low-dimensional mathematical model of ordinary differential equations to describe TNF-\n                    <jats:inline-formula>\n                      <jats:alternatives>\n                        <jats:tex-math>$$\\alpha $$<\/jats:tex-math>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                          <mml:mi>\u03b1<\/mml:mi>\n                        <\/mml:math>\n                      <\/jats:alternatives>\n                    <\/jats:inline-formula>\n                    dynamics, its interactions with receptors and infliximab, and the influence of drug clearance on treatment outcomes in CD and UC. This model is combined with a pharmacokinetic framework that enables the estimation of the infliximab clearance coefficient, which can then be used to guide dosage adjustments in the treatment. The model balances biological realism with analytical tractability, enabling rigorous mathematical analysis and numerical simulations. The parameters are adapted for CD and UC. The study investigates how drug clearance influences treatment efficacy, initially using constant clearance values and later incorporating values that vary with the level of inflammation. Simulations are performed across a range of clearance rates and dosing regimens, providing detailed insights into infliximab and TNF-\n                    <jats:inline-formula>\n                      <jats:alternatives>\n                        <jats:tex-math>$$\\alpha $$<\/jats:tex-math>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                          <mml:mi>\u03b1<\/mml:mi>\n                        <\/mml:math>\n                      <\/jats:alternatives>\n                    <\/jats:inline-formula>\n                    dynamics, as well as therapeutic drug monitoring parameters. Our results highlight the critical role of clearance and therapeutic drug monitoring in optimizing infliximab therapy. This approach offers valuable insights to support personalized treatment strategies in IBD.\n                  <\/jats:p>","DOI":"10.1007\/s11538-026-01603-9","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:34:59Z","timestamp":1770892499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A mathematical model to simulate the biological action of Infliximab on TNF-$$\\alpha $$ in patients with Inflammatory Bowel Disease: the critical role of drug clearance"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-5033","authenticated-orcid":false,"given":"Ana M.","family":"Portillo","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-9153","authenticated-orcid":false,"given":"\u00c1ngel","family":"De Prado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4771-9859","authenticated-orcid":false,"given":"Ana J.","family":"Soares","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"10114","key":"1603_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JC, Chan FK et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet 390(10114):2769\u20132778","journal-title":"The Lancet"},{"issue":"1","key":"1603_CR2","first-page":"7247238","volume":"2019","author":"Q Guan","year":"2019","unstructured":"Guan Q (2019) A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019(1):7247238","journal-title":"J Immunol Res"},{"issue":"3","key":"1603_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/08923979209005404","volume":"14","author":"M Maeda","year":"1992","unstructured":"Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, Tsuji Y, Akiyama S, Tsuji N, Niitsu Y (1992) Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 14(3):451\u2013461","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1603_CR4","doi-asserted-by":"crossref","unstructured":"Owczarek D, Cibor D, G\u0142owacki M, Cie\u015bla A, Mach P (2012) Tnf-$$\\alpha $$ and soluble forms of tnf receptors 1 and 2 in the serum of patients with crohn\u2019s disease and ulcerative colitis","DOI":"10.20452\/pamw.1537"},{"issue":"5","key":"1603_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/med.21893","volume":"42","author":"D Liu","year":"2022","unstructured":"Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS (2022) Inflammatory bowel disease biomarkers. Med Res Rev 42(5):1856\u20131887","journal-title":"Med Res Rev"},{"issue":"23","key":"1603_CR6","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462\u20132476","journal-title":"N Engl J Med"},{"issue":"9317","key":"1603_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W et al (2002) Maintenance infliximab for crohn\u2019s disease: the accent i randomised trial. The Lancet 359(9317):1541\u20131549","journal-title":"The Lancet"},{"issue":"12","key":"1603_CR8","first-page":"656","volume":"15","author":"S Fine","year":"2019","unstructured":"Fine S, Papamichael K, Cheifetz AS (2019) Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterology & hepatology 15(12):656","journal-title":"Gastroenterology & hepatology"},{"issue":"5","key":"1603_CR9","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1007\/s10787-024-01508-w","volume":"32","author":"ME Kamal","year":"2024","unstructured":"Kamal ME, Werida RH, Radwan MA, Askar SR, Omran GA, El-Mohamdy MA, Hagag RS (2024) Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology 32(5):3259\u20133269","journal-title":"Inflammopharmacology"},{"issue":"9","key":"1603_CR10","doi-asserted-by":"publisher","first-page":"0238918","DOI":"10.1371\/journal.pone.0238918","volume":"15","author":"A Park","year":"2020","unstructured":"Park A, Kim S, Jung IH, Byun JH (2020) An immune therapy model for effective treatment on inflammatory bowel disease. PLoS ONE 15(9):0238918","journal-title":"PLoS ONE"},{"issue":"1","key":"1603_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/cts.12849","volume":"14","author":"KV Rogers","year":"2021","unstructured":"Rogers KV, Martin SW, Bhattacharya I, Singh RSP, Nayak S (2021) A dynamic quantitative systems pharmacology model of inflammatory bowel disease: Part 1-model framework. Clin Transl Sci 14(1):239\u2013248","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1603_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/cts.12850","volume":"14","author":"KV Rogers","year":"2021","unstructured":"Rogers KV, Martin SW, Bhattacharya I, Singh RSP, Nayak S (2021) A dynamic quantitative systems pharmacology model of inflammatory bowel disease: part 2-application to current therapies in crohn s disease. Clin Transl Sci 14(1):249\u2013259","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1603_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/rheumatology\/keh491","volume":"44","author":"M Jit","year":"2005","unstructured":"Jit M, Henderson B, Stevens M, Seymour R (2005) Tnf-$$\\alpha $$ neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. Rheumatology 44(3):323\u2013331","journal-title":"Rheumatology"},{"issue":"2","key":"1603_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1073\/pnas.95.2.570","volume":"95","author":"M Grell","year":"1998","unstructured":"Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (cd120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci 95(2):570\u2013575","journal-title":"Proc Natl Acad Sci"},{"key":"1603_CR15","doi-asserted-by":"crossref","unstructured":"Imamura K, Spriggs D, Kufe D (1987) Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. Journal of immunology (Baltimore, Md.: 1950) 139(9), 2989\u20132992","DOI":"10.4049\/jimmunol.139.9.2989"},{"key":"1603_CR16","doi-asserted-by":"crossref","unstructured":"Mosselmans R, Hepburn A, Dumont JE, Fiers W, Galand P (1988) Endocytic pathway of recombinant murine tumor necrosis factor in l-929 cells. Journal of immunology (Baltimore, Md.: 1950) 141(9), 3096\u20133100","DOI":"10.4049\/jimmunol.141.9.3096"},{"issue":"11","key":"1603_CR17","first-page":"3146","volume":"50","author":"DM Smith","year":"1990","unstructured":"Smith DM, Lackides GA, Epstein LB (1990) Coordinated induction of autocrine tumor necrosis factor and interleukin 1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity. Can Res 50(11):3146\u20133153","journal-title":"Can Res"},{"issue":"8","key":"1603_CR18","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1073\/pnas.89.8.3338","volume":"89","author":"SH Northrup","year":"1992","unstructured":"Northrup SH, Erickson HP (1992) Kinetics of protein-protein association explained by brownian dynamics computer simulation. Proc Natl Acad Sci 89(8):3338\u20133342","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"1603_CR19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1073\/pnas.92.5.1254","volume":"92","author":"J Foote","year":"1995","unstructured":"Foote J, Eisen HN (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci 92(5):1254\u20131256","journal-title":"Proc Natl Acad Sci"},{"issue":"Suppl 3","key":"1603_CR20","first-page":"124","volume":"59","author":"C Wagner","year":"1998","unstructured":"Wagner C, Mace K, DeWoody K, Zelinger D, Leone A, Schaible T, Shealy D (1998) Infliximab treatment benefits correlate with pharmacodynamic parameters in crohn\u2019s disease patients. Digestion 59(Suppl 3):124\u20135","journal-title":"Digestion"},{"key":"1603_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","volume":"46","author":"U Klotz","year":"2007","unstructured":"Klotz U, Teml A, Schwab M (2007) Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 46:645\u2013660","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1603_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/clinchem\/47.7.1297","volume":"47","author":"M Komatsu","year":"2001","unstructured":"Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, Tsuji N, Sakamaki S, Niitsu Y, Watanabe N (2001) Tumor necrosis factor-$$\\alpha $$ in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-pcr. Clin Chem 47(7):1297\u20131301","journal-title":"Clin Chem"},{"key":"1603_CR23","volume-title":"The Qualitative Theory of Ordinary Differential Equations: an Introduction","author":"F Brauer","year":"1989","unstructured":"Brauer F, Nohel JA (1989) The Qualitative Theory of Ordinary Differential Equations: an Introduction. Courier Corporation, Mineola, NY"},{"key":"1603_CR24","doi-asserted-by":"crossref","unstructured":"Brandse JF, Brink GR, Wildenberg ME, Kleij D, Rispens T, Jansen JM, Math\u00f4t RA, Ponsioen CY, L\u00f6wenberg M, D Haens GR (2015) Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149(2), 350\u2013355","DOI":"10.1053\/j.gastro.2015.04.016"},{"issue":"11","key":"1603_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1096\/fasebj.11.11.9285481","volume":"11","author":"JN Weiss","year":"1997","unstructured":"Weiss JN (1997) The hill equation revisited: uses and misuses. FASEB J 11(11):835\u2013841. https:\/\/doi.org\/10.1096\/fasebj.11.11.9285481","journal-title":"FASEB J"},{"issue":"4","key":"1603_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/bioinformatics\/13.4.377","volume":"13","author":"J-HS Hofmeyr","year":"1997","unstructured":"Hofmeyr J-HS, Cornish-Bowden A (1997) Hill equation: how to incorporate cooperative enzymes into metabolic models. Bioinformatics 13(4):377\u2013385. https:\/\/doi.org\/10.1093\/bioinformatics\/13.4.377","journal-title":"Bioinformatics"},{"issue":"3","key":"1603_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/bcp.12087","volume":"76","author":"D Ternant","year":"2013","unstructured":"Ternant D, Paintaud G et al (2013) Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 76(3):438\u2013447. https:\/\/doi.org\/10.1111\/bcp.12087","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1603_CR28","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/apt.14193","volume":"45","author":"MF Pouw","year":"2017","unstructured":"Pouw MF, Zande JJ, Hulst L et al (2017) A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 45(10):1335\u20131344. https:\/\/doi.org\/10.1111\/apt.14193","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"10","key":"1603_CR29","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, Warusavitarne J, Agrawal M, Allocca M, Atreya R et al (2024) Ecco guidelines on therapeutics in crohn s disease: medical treatment. J Crohns Colitis 18(10):1531\u20131555","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1603_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W et al (2022) Ecco guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 16(1):2\u201317","journal-title":"J Crohns Colitis"},{"issue":"5","key":"1603_CR31","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/MEG.0000000000001706","volume":"32","author":"M Chaparro","year":"2020","unstructured":"Chaparro M, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, Garc\u00eda-S\u00e1nchez V, Mar\u00edn-Jim\u00e9nez I, Barreiro-de Acosta M, Vera I et al (2020) Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with crohn s disease. European Journal of Gastroenterology & Hepatology 32(5):588\u2013596","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"3","key":"1603_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/gutjnl-2024-333385","volume":"74","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Ben\u00edtez J-M, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D et al (2025) Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of geteccu. Gut 74(3):387\u2013396","journal-title":"Gut"},{"issue":"4","key":"1603_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.cgh.2020.03.066","volume":"19","author":"B Jessen","year":"2021","unstructured":"Jessen B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, Kruglov A, Freise I, Schmidt F, Maul J, K\u00fchl AA, Glauben R et al (2021) Level of tumor necrosis factor production by stimulated blood mononuclear cells can be used to predict response of patients with inflammatory bowel diseases to infliximab. Clin Gastroenterol Hepatol 19(4):721\u2013731","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1603_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.881112","volume":"13","author":"G Cui","year":"2022","unstructured":"Cui G, Florholmen J, Goll R (2022) Could mucosal tnf transcript as a biomarker candidate help optimize anti-tnf biological therapy in patients with ulcerative colitis? Front Immunol 13:881112","journal-title":"Front Immunol"},{"key":"1603_CR35","doi-asserted-by":"crossref","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van\u00a0Assche G, et al.: (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 381(13), 1201\u20131214","DOI":"10.1056\/NEJMoa1900750"},{"issue":"20","key":"1603_CR36","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao L-L, Miao Y et al (2016) Ustekinumab as induction and maintenance therapy for crohn s disease. N Engl J Med 375(20):1946\u20131960","journal-title":"N Engl J Med"},{"key":"1603_CR37","doi-asserted-by":"crossref","unstructured":"Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel J-F, Parkes G, Peyrin-Biroulet L, D Haens G, Hisamatsu T, et al.: (2024) Risankizumab for ulcerative colitis: two randomized clinical trials. Jama 332(11), 881\u2013897","DOI":"10.1001\/jama.2024.12414"},{"key":"1603_CR38","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel J-F, Caprioli F, D Haens G, Ferrante M, Schreiber S., Atreya R, Danese S, Lindsay JO, et al.: (2024) Risankizumab versus ustekinumab for moderate-to-severe crohn s disease. New England Journal of Medicine 391(3), 213\u2013223","DOI":"10.1056\/NEJMoa2314585"},{"key":"1603_CR39","doi-asserted-by":"crossref","unstructured":"D haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, et al.: (2023) Mirikizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 388(26), 2444\u20132455","DOI":"10.1056\/NEJMoa2207940"},{"issue":"10470","key":"1603_CR40","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, d\u2019Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM et al (2024) Efficacy and safety of mirikizumab in patients with moderately-to-severely active crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. The Lancet 404(10470):2423\u20132436","journal-title":"The Lancet"},{"issue":"8","key":"1603_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, Van Assche G, Axler J, Kim H-J, Danese S et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699\u2013710","journal-title":"N Engl J Med"},{"issue":"8","key":"1603_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B et al (2013) Vedolizumab as induction and maintenance therapy for crohn\u2019s disease. N Engl J Med 369(8):711\u2013721","journal-title":"N Engl J Med"},{"key":"1603_CR43","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Su C, Sands BE, D Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, et al.: (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 376(18), 1723\u20131736","DOI":"10.1056\/NEJMoa1606910"},{"issue":"6","key":"1603_CR44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D\u2019Haens G, Panaccione R, Higgins PD, Colombel J-F, Feagan BG et al (2017) Tofacitinib for induction and maintenance therapy of crohn\u2019s disease: results of two phase iib randomised placebo-controlled trials. Gut 66(6):1049\u20131059","journal-title":"Gut"},{"issue":"10341","key":"1603_CR45","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, H\u00e9buterne X, D\u2019Haens G, Nakase H, Pan\u00e9s J et al (2022) Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. The lancet 399(10341):2113\u20132128","journal-title":"The lancet"},{"key":"1603_CR46","doi-asserted-by":"crossref","unstructured":"Loftus\u00a0Jr, EV, Pan\u00e9s J, Lacerda AP, Peyrin-Biroulet L, D Haens G, Panaccione R, Reinisch W, Louis E, Chen M, Nakase H, et al.: (2023) Upadacitinib induction and maintenance therapy for crohn s disease. New England Journal of Medicine 388(21), 1966\u20131980","DOI":"10.1056\/NEJMoa2212728"},{"issue":"2","key":"1603_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/jcph.1732","volume":"61","author":"A Eser","year":"2021","unstructured":"Eser A, Reinisch W, Schreiber S, Ahmad T, Boulos S, Mould DR (2021) Increased induction infliximab clearance predicts early antidrug antibody detection. J Clin Pharmacol 61(2):224\u2013233","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1603_CR48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","volume":"23","author":"JF Brandse","year":"2017","unstructured":"Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, Brink GR, D\u2019Haens GR (2017) A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis 23(4):650\u2013660","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1603_CR49","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/bcp.14229","volume":"86","author":"JG S\u00e1nchez-Hern\u00e1ndez","year":"2020","unstructured":"S\u00e1nchez-Hern\u00e1ndez JG, Rebollo N, Martin-Suarez A, Calvo MV, Mu\u00f1oz F (2020) A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol 86(6):1165\u20131175","journal-title":"Br J Clin Pharmacol"}],"container-title":["Bulletin of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-026-01603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11538-026-01603-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-026-01603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:36:56Z","timestamp":1773067016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11538-026-01603-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1007\/s11538-026-01603-9","relation":{},"ISSN":["0092-8240","1522-9602"],"issn-type":[{"value":"0092-8240","type":"print"},{"value":"1522-9602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"\u2018Not applicable\u2019","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u2018Not applicable\u2019","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used in this study were obtained from previously published articles and are publicly available. \u2018Not applicable\u2019","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Materials availability"}},{"value":"The code is easily reproducible. The appendix includes, as an example, the MATLAB code used to generate Figure 5(a).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}],"article-number":"38"}}